1 / 22

“ Update and new perspectives on HSV infections ”

21st World Congress of Dermatology Oct/2007. “ Update and new perspectives on HSV infections ”. Paulo R. Cunha, MD, PhD. Professor of Dermatology Jundiaí Medical School São Paulo, Brazil. Introduction. Over 70% of the population has been infected by either HSV-1 or HSV-2

xia
Download Presentation

“ Update and new perspectives on HSV infections ”

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. 21st World Congress of Dermatology Oct/2007 “Update and new perspectives on HSV infections” Paulo R. Cunha, MD, PhD. Professor of Dermatology Jundiaí Medical School São Paulo, Brazil

  2. Introduction • Over 70% of the population has been infected by either HSV-1 or HSV-2 • Produce: primary, latent and recurrent infections. • Clinical manifestation: “benign and malign” • Extragenital Herpes: • 80-90%: HSV-1 • Genital Herpes: (normally sexual transmission) • 80-90%: HSV-2

  3. DNA Virus Serological techniques: HSV-1: glycoprotein gC1 HSV-2: glycoproteingC2

  4. Keratinocyte Cytoplasm Herpes virus Capsid Cell membrane Virus new particle DNA HSV Capsomers

  5. Acyclovir Cytoplasmic Membrane Timidina Kinase (TK) Acyclovir Monophosphate Acyclovir Triphosphate

  6. Valacyclovir 1000 bid 500 bid (3†-5 d) 500 qd‡ 1000 qd (5 d) 1000 qd Acyclovir 400 tid 400 tid (5 d) 400 bid 200 5/day 800 bid (5 d) 200 5/day (5 d) Famcyclovir 250 tid* 125 bid (5 d) 250 bid up to 1 year Genital Herpes: CDC Treatment Recommendations First clinical Recurrent genital herpes genital herpes episode episodic suppressive(mg for 7–10 days) (mg  days) (mg, daily) *Not FDA approved †New FDA-approved dosing ‡May be less effective in patients who have very frequent recurrences (10 episodes/year) Centers for Disease Control and Prevention. MMWR. 2002;51(RR-6)12-17.

  7. Issues to be considered in Suppressive Therapy • Not necessary to wait 6 outbreaks in 12 months • Define impact of genital herpes • Gravity and duration of the outbreak

  8. New Therapeutic Options 1)Analog of nucleoside • Cidofovir (gel 0.3 or 1%) Single-dose confers a significant antiviral effect on lesions of recurrent genital herpes. Antimicrob Agents Chemother 1998 Nov;42(11):2996-9

  9. New Therapeutic Options2)Immunomodulator • Resiquimod (gel 0.05%) Significant reduction in number of recurrences J Infect Dis 2001 Jul 15;184(2):196-200

  10. New Therapeutic Options3) Fusion Inhibitor • Docosanol (Abreva®) (cream 10%) interferes with the process of viral fusion with the host cell. Effective treatment for recurrent HSL. J Am Acad Dermatol 2001 Aug; 45 (2): 222-30)

  11. New Therapeutic Options4) Direct action in DNA polimerase of HSV • Foscarnet is the choice in pts with HSV resistant to acyclovir. It is effective in destroying the virus timidina kinase lacking (nephrotoxicity). Rio Dermatológico 2001 July/August/September • Foscarnet (cream 2%) is an effective and safe medication in the treatment of HSL. Hautarzt. 2006 Jan;57(1):40-6

  12. New Therapeutic Options 5)Helicase inhbitors (Phase III) Could increase the intervals between the crises and it is more effective then acyclovir Nature Med. 8,392-398, 2002). (Phase III)

  13. Treatment of Recurrent Herpes Simplex with L-LysineDecreases recurrence and severity Long-term: L-Lysine 1 g/day Avoid: Arginine, “Herpetogenic” foods like chocolate, peas, cola drinks, grain cereals, peanuts, gelatin, cashews, beer. Encourage: Lysine, Foods like dairy products, milk, potatoes, brewer’s yeast.

  14. New Antiherpes Vaccines by Genetic Engineering • An ideal vaccine should induce Cellular and Humoral Immune Response adequate to prevent infection.

  15. Vaccines by genetic engineering PCMVT7His6EK BGH f1 SV40N SV40 ColE1 Amp pA ori ori pA Vaccines with DNA of plasmid that contains the codes of viral glycoproteins (pcDNA3.1/His A,B,C 5.5 kb ) transformed bacteria Plasmid insertion Plasmid transference Chromosome

  16. Cellular and Humoral Immune Response

  17. Herpes Virus Vaccine: News and Perspectives • The most hopeful result was obtained with HSV-2 gD2 and alum/MPL vaccine (Glaxo SmithKline) in clinical studies. -74% effective in preventing genital disease -Only in women who had never been exposed to HSV previously. -Not effective in men

  18. Herpes Virus Vaccine: News and Perspectives DISC (Disabled Infectious Single Cycle) virus HSV vaccine contains a virus with deletion of an essential gene (gH gene), so the replication has been limited to a single cycle only. Guinea pigs were protected from a primary infection. Significant protection from recurrent disease was also observed.

  19. Herpes Virus Vaccine Studies Prophylactic Vaccines for HSV-2 Genetically engineered HSV to produce a vaccine that is protective without causing human disease is in development. Using a vaccine with live attenuated HSV from which neurovirulence gene (gamma 1 34.5) has been removed, has debilitated HSV in its ability to establish latency and be reactivated. Animals vaccinated are able to elicit protective immune responses Mikrobiyol Bul. 2006 Oct;40(4):413-33

  20. Conclusions • HSV Vaccine is still a challenge. • Seronegative individuals at high risk for infection represent ideal candidates for vaccine trials. • Individuals with frequent recurrences are not significantly responsive to vaccines so far. • Promising approaches to engineered HSV vaccines should be possible within the next several years. • We are in the right road but we have to keep walking. • Sexual education, campaigns of information and the use of preservative continues to be essential.

  21. Thank you! drpaulocunha@bol.com.br

More Related